Annakaisa Haapasalo Group (Molecular Neurodegeneration)

Our research focus lies in the genetic background and molecular mechanisms underpinning neurodegenerative diseases, especially frontotemporal dementia (FTD). To this end, we utilize a variety of in vitro and in vivo model systems and patient-derived cells, clinical samples and data. We are especi...

CROSSHARES consortium - hare research

Our research group is a part of the CROSSHARES consortium, studying the biological consequences of hybridisation between mountain hare and brown hare, broadly utilising state-of-the-art methods in genomics and molecular biology.

Dorit Hoffmann

Tutkijatohtori, Postdoctoral researcher, A.I. Virtanen Institute for Molecular Sciences

Immuno-Ophthalmology

Inflammation is associated with various chronic diseases many of which have insufficient treatment options. Along with inflammatory signaling, we study more broadly cellular events in order to reveal molecular mechanisms and dysfunctionalities behind the pathogenesis of inflammatory diseases.

Martikainen lab

Our research group is interested in mitochondrial disease. As a model system we use patient specific stem cell-derived cell lines, specifically neuronal and cardiac cell cultures.

Mitochondrial biology

Our group investigates the role of mitochondrial DNA maintenance as well as its role for the healthy function of cells and tissues, applying diverse methods in molecular biology and genomics.

Neurobiology of disease

The main goal of our research is to understand the mechanisms that lead to neurodegenerative diseases and to identify novel therapeutic approaches for them. We are interested in the effects of environmental factors (such as air pollution and viral infections) and lifestyle factors on brain healt...

Redox signaling (Anna-Liisa Levonen group)

Nrf2 is a transcription factor mainly involved in combating cellular stress caused by reactive oxygen and nitrogen species. However, Nrf2 is also involved in cancer and cardiometabolic diseases, making it an essential drug target.

Riikka Lampinen

Nuorempi tutkija, A.I. Virtanen Institute for Molecular Sciences